# Zanamivir (hydrate)(5:1)

Cat. No.: HY-13210A CAS No.: 171094-50-1

Molecular Formula:  $C_{12}H_{20\cdot4}N_4O_{7\cdot2}$ Molecular Weight: 335.91

Antibiotic; Influenza Virus Target:

Pathway: Anti-infection

Storage: Please store the product under the recommended conditions in the Certificate of

**Product** Data Sheet

## **BIOLOGICAL ACTIVITY**

Description	Zanamivir hydrate (5:1) is the hydrate of Zanamivir. Zanamivir is an influenza viral neuraminidase inhibitor with IC $_{50}$ values of 0.95 nM and 2.7 nM for influenza A and B, respectively <sup>[1]</sup> .
IC <sub>50</sub> & Target	IC <sub>50</sub> : 0.95 nM (Influenza A); 2.7 nM (Influenza B) <sup>[1]</sup>
In Vivo	Zanamivir has a poor bioavailability in oral administration, with only 4-17% of the agent. Oral delivery of Zanamivir has been a problem due to its strong hydrophilic nature that limits its transport across the intestinal epithelium. Permeation enhancers such as sodium cholate, hydroxypropyl β-cyclodextrin could be used with zanamivir to enhance the intestinal permeability <sup>[3]</sup> .  MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## **CUSTOMER VALIDATION**

- Signal Transduct Target Ther. 2021 Apr 24;6(1):165.
- Antimicrob Agents Chemother. 2020 Jun 23;64(7):e00222-20.
- PLoS One. 2018 Jul 12;13(7):e0200761.
- · bioRxiv. 2020 Mar.
- bioRxiv. July 26, 2018.

See more customer validations on www.MedChemExpress.com

### **REFERENCES**

[1]. Gubareva LV, et al. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates ofinfluenza virus and neuraminidase inhibitorresistant variants. Antimicrob Agents Chemother. 2001 Dec;45(12):3403-8.

[2]. McKimm-Breschkin JL, et al. Management of influenza virus infections with neuraminidase inhibitors: detection, incidence, and implications of drug resistance. Treat Respir Med. 2005;4(2):107-16.

B]. Shanmugam S, et al. Zanami	ivir oral delivery: enhanced pla	asma and lung bioavailability in	rats. Biomol Ther (Seoul). 2013 Mar;21(2):16	51-9.
			ical applications. For research use onl	
	Tel: 609-228-6898 Address: 1 De	Fax: 609-228-5909 eer Park Dr, Suite Q, Monmou	E-mail: tech@MedChemExpress.com th Junction, NJ 08852, USA	m

Page 2 of 2 www.MedChemExpress.com